ESR1 and colorectal carcinoma: Taking into consideration the data presented above and the possibility that women (the post-menopausal women, in particular) might associate an nutraceutical based on GEN (which act as an ER agonist) and ASA – as chemoprevention for CRC, the present study investigated the effects of an ASA+GEN combination in human colorectal cancer cells (HCT-116) by performing: (i) an in vitro evaluation of cell viability, cell morphology changes, and migratory and invasion potential, and (ii) an in ovo analysis to determine the antiangiogenic activity.